Jazz Seeks To Augment Rare Cancer Portfolio With Chimerx Buyout

 
• By Joseph Haas
  
Jazz Pharmaceuticals
Jazz Pharmaceuticals will pay $935m to acquire Chimerx (Shutterstock)

More from Deals

More from Therapy Areas